Triple Giving November OMF logo

 TRIPLE YOUR IMPACT during Triple Giving November | All Donations to OMF are TRIPLED through December 3

Search
Close this search box.

Precision Medicine for Myalgic Encephalomyelitis
Drug Discovery and ClinicaI Trials (REMEDIAL)

The REMEDIAL project continues the work commenced with MAESTRO and will lead to a better understanding of the molecular mechanisms underlying ME/CFS pathophysiology, the persistence and variability of the symptoms, and will contribute to the identification of targets and therapeutic agents for intervention.

  • Alain Moreau, PhD

We conducted a comprehensive analysis and found 27 circulating microRNAs that were significantly different in people with ME/CFS and POTS (postural orthostatic tachycardia syndrome) compared to those with ME/CFS alone or POTS alone.

  • We identified two microRNAs that were only elevated in patients with both ME and POTS, and two others that were elevated only in patients with POTS but not ME.
  • By examining the targets of these microRNAs, we discovered new genes and proteins that could lead to new treatment options.
  • We also found a potential shared mechanism between people with both ME and POTS and those with POTS alone, which involves dopamine receptors.


Cognitive assessments using BrainCheck enabled the stratification of ME/CFS patients into three distinct clusters based on cognitive response.

  • These clusters led us to discover specific microRNAs associated with particular cognitive domains, which may provide insight into mechanisms underlying cognitive impairment in ME/CFS.
  • Our studies have identified three key microRNAs—miR-29a-3p, miR-150-5p, and the miR-181 family—that show promising connections to cognitive function and decline in the context of ME/CFS.


Multiple manuscripts on this work are in preparation.

STUDY HYPOTHESIS AND DESCRIPTION

Our study will couple a deep phenotyping
characterization of ME/CFS patients to the
development of cellular and animal models
for repurposing current drugs to accelerate
the proof-of-concept of different therapeutic
interventions for ME/CFS. Indeed, precision
medicine is essential to address the clinical
complexity of ME/CFS and to identify the
best therapeutic options to cure ME/CFS.

 

OBJECTIVES

  • Deep phenotyping of ME patients through precision medicine.
  • Development of cellular and mouse models for the validation of targets.
  • Preparation and launch of pilot phase 2b clinical trials..
Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

What are the advantages of giving from your Donor Advised Fund (DAF)?

  • Your gifts to your donor advised fund entitle you to an immediate income tax deduction at the time of contribution.
  • You avoid capital gains tax on appreciated assets you place in your donor advised fund.
  • Your fund’s investment gains accumulate tax free.
  • Funds are distributed to Open Medicine Foundation in your name and immediately put to use to support our worldwide research efforts.


How do I make a donation through my DAF?

Just click on the DAF widget below. It is simple and convenient to find your fund among the over 900 funds in our system.

Still can’t find your fund? 

  • Request a grant distribution through your Donor Advised Fund sponsor
  • Be sure to use OMF’s EIN #26-4712664
  • You can also designate OMF as a beneficiary for your Donor Advised Fund
  • Questions? Give us a call at 650-242-8669